ITEM 5.02.                 Departure of Directors or Certain Officers; Election of Directors;
                           Appointment of Certain Officers; Compensatory Arrangements of Certain
                           Officers.


On December 18, 2020, the Board of Directors of OPKO Health, Inc. (the
"Company"), appointed Roger J. Medel, M.D. as a new director with immediate
effect to serve until the Company's 2021 Annual Meeting of Stockholders and
until his successor shall be duly elected or appointed or his earlier death or
resignation. Dr. Medel has not been named to any committees of the Board of
Directors at this time. There is no arrangement or understanding between Dr.
Medel and any other persons pursuant to which Dr. Medel was selected as a
director. The Board has determined that Dr. Medel is independent under the
applicable rules of the Securities and Exchange Commission and the Nasdaq Stock
Market.
Dr. Medel is the co-founder of MEDNAX, Inc., a national health solutions partner
comprised of the nation's leading providers of physician services, and has
served as a director of MEDNAX since 1979. Dr. Medel served as MEDNAX's
President until May 2000 and again from March 2003 until May 2004. He served as
Chief Executive Officer of MEDNAX from 1979 until December 2002, and again from
March 2003 until July 2020 when he retired. Dr. Medel has served as a member of
the Board of Trustees of the Dana Farber Cancer Institute, Inc. since January
2016. He was a member of the Board of Trustees of the University of Miami from
January 2004 to February 2012. Dr. Medel actively participates as a member of
several medical and professional organizations and from June 2006 to April 2009,
served on the Board of Directors of MBF Healthcare Acquisition Corp.
GeneDx Inc. ("GeneDx"), a subsidiary of the Company, is a party to a joint
venture with Mednax Services, Inc. ("Mednax Services"), a subsidiary of MEDNAX.
Upon its formation in August 2020, GeneDx contributed $245,000 to the joint
venture, and Mednax Services contributed $255,000. Adam Logal, the Company's
CFO, is the chair and sits on the Board of Managers of the joint venture. Mednax
Services provides administrative services to the joint venture pursuant to an
administrative services agreement. GeneDx provides laboratory services to the
joint venture.
Except as described above, since the beginning of the Company's last fiscal
year, the Company has not engaged in any transaction, or any currently proposed
transaction, in which Dr. Medel had or will have a direct or indirect material
interest that would require disclosure pursuant to Item 404(a) of Regulation S-K
promulgated by the Securities and Exchange Commission.
Dr. Medel will participate in the standard non-employee director compensation
arrangements described in the section entitled "Director Compensation" that is
included in the Company's 2020 Proxy Statement on Schedule 14A filed with the
Securities and Exchange Commission on April 29, 2020. The Company has also
entered into its standard director indemnification agreement with Dr. Medel, a
form of which has been filed or incorporated by reference as Exhibit 10.3 to the
Company's Annual Report on Form 10-K for the year ended December 31, 2019 filed
with the SEC on March 2, 2020.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses